Irhythm Technologies [IRTC] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Irhythm Technologies
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Irhythm Technologies wins in 5 metrics, Abbott Laboratories wins in 13 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Irhythm Technologies | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -43.66 | 16.83 | Irhythm Technologies |
| Price-to-Book Ratio | 49.09 | 4.62 | Abbott Laboratories |
| Debt-to-Equity Ratio | 708.80 | 26.50 | Abbott Laboratories |
| PEG Ratio | -86.14 | 26.02 | Irhythm Technologies |
| EV/EBITDA | -111.34 | 20.97 | Irhythm Technologies |
| Profit Margin (TTM) | -14.06% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | -5.71% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | N/A | 19.73% | N/A |
| Return on Equity | -91.14% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | -3.53% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $-45.55M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | 123.27% | 23.52% | Irhythm Technologies |
| Price-to-Sales Ratio (TTM) | 7.75 | 5.42 | Abbott Laboratories |
| Enterprise Value | $5.28B | $240.16B | Abbott Laboratories |
| EV/Revenue Ratio | 8.04 | 5.57 | Abbott Laboratories |
| Gross Profit Margin (TTM) | 71.17% | 56.44% | Irhythm Technologies |
| Revenue per Share (TTM) | $21 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $-2.92 | $7.98 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.41 | 0.71 | Abbott Laboratories |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Irhythm Technologies vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Irhythm Technologies | -1.55% | -3.92% | 17.73% | 15.69% | 44.75% | 77.21% |
| Abbott Laboratories | 1.68% | 5.49% | 0.69% | 0.21% | 2.26% | 18.37% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Irhythm Technologies | 123.27% | 4.68% | -8.36% | 514.58% | 514.58% | 514.58% |
| Abbott Laboratories | 23.52% | 20.45% | 34.29% | 167.33% | 459.03% | 501.34% |
Performance & Financial Health Analysis: Irhythm Technologies vs Abbott Laboratories
| Metric | IRTC | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $5.09B | $233.71B |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 678,940 | 5,741,100 |
| 90 Day Avg. Volume | 508,497 | 7,119,163 |
| Last Close | $158.50 | $134.28 |
| 52 Week Range | $55.92 - $168.32 | $107.11 - $141.23 |
| % from 52W High | -5.83% | -4.92% |
| All-Time High | $286.19 (Jan 25, 2021) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -44.62% | -5.83% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.26% | 0.07% |
| Quarterly Earnings Growth | 0.26% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.14% | 0.32% |
| Operating Margin (TTM) | -0.06% | 0.20% |
| Return on Equity (TTM) | -0.91% | 0.31% |
| Debt to Equity (MRQ) | 708.80 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $3.23 | $29.05 |
| Cash per Share (MRQ) | $16.98 | $4.18 |
| Operating Cash Flow (TTM) | $63.35M | $9.04B |
| Levered Free Cash Flow (TTM) | $47.56M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Irhythm Technologies vs Abbott Laboratories
| Metric | IRTC | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -43.66 | 16.83 |
| Forward P/E | -86.14 | 26.02 |
| PEG Ratio | -86.14 | 26.02 |
| Price to Sales (TTM) | 7.75 | 5.42 |
| Price to Book (MRQ) | 49.09 | 4.62 |
| Market Capitalization | ||
| Market Capitalization | $5.09B | $233.71B |
| Enterprise Value | $5.28B | $240.16B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.04 | 5.57 |
| Enterprise to EBITDA | -111.34 | 20.97 |
| Risk & Other Metrics | ||
| Beta | 1.41 | 0.71 |
| Book Value per Share (MRQ) | $3.23 | $29.05 |
Financial Statements Comparison: Irhythm Technologies vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IRTC | ABT |
|---|---|---|
| Revenue/Sales | $158.68M | $10.36B |
| Cost of Goods Sold | $49.46M | $4.47B |
| Gross Profit | $109.22M | $5.89B |
| Research & Development | $21.82M | $716.00M |
| Operating Income (EBIT) | $-32.56M | $1.69B |
| EBITDA | $-20.95M | $2.66B |
| Pre-Tax Income | $-30.04M | $1.78B |
| Income Tax | $665,000 | $453.00M |
| Net Income (Profit) | $-30.70M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IRTC | ABT |
|---|---|---|
| Cash & Equivalents | $375.28M | $6.53B |
| Total Current Assets | $636.01M | $23.15B |
| Total Current Liabilities | $111.34M | $13.00B |
| Long-Term Debt | $719.36M | $12.74B |
| Total Shareholders Equity | $86.67M | $49.06B |
| Retained Earnings | $-789.60M | $47.72B |
| Property, Plant & Equipment | $55.71M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IRTC | ABT |
|---|---|---|
| Operating Cash Flow | $-31.20M | $1.42B |
| Capital Expenditures | $-9.42M | $-484.00M |
| Free Cash Flow | $-17.31M | $933.00M |
| Debt Repayment | $0 | $-1.00B |
| Common Stock Repurchase | $0 | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | IRTC | ABT |
|---|---|---|
| Shares Short | 2.49M | 19.06M |
| Short Ratio | 5.55 | 3.12 |
| Short % of Float | 0.09% | 0.01% |
| Average Daily Volume (10 Day) | 678,940 | 5,741,100 |
| Average Daily Volume (90 Day) | 508,497 | 7,119,163 |
| Shares Outstanding | 31.39M | 1.73B |
| Float Shares | 31.74M | 1.73B |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.14% | 0.81% |
Dividend Analysis & Yield Comparison: Irhythm Technologies vs Abbott Laboratories
| Metric | IRTC | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |